Payneri personal page - To The Moon

Payneri

Payneri

No personal profile

4Follow

1Followers

0Topic

0Badge

2023-01-15

Not sure I agree with the Apple assessment.

3 Warren Buffett Stocks to Avoid Like the Plague in 2023

2022-06-16

$Genius Group Limited(GNS)$Looking good!!!

2022-05-27

Interesting view

7 Undervalued Blue-Chip Stocks to Buy for June

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4110126448550012,"uuid":"4110126448550012","gmtCreate":1647031572947,"gmtModify":1653581735638,"name":"Payneri","pinyin":"payneri","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/f523c00ecd00b27a2a30216bac7505e7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9958257664,"gmtCreate":1673755775758,"gmtModify":1676538882140,"author":{"id":"4110126448550012","authorId":"4110126448550012","name":"Payneri","avatar":"https://community-static.tradeup.com/news/f523c00ecd00b27a2a30216bac7505e7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Not sure I agree with the Apple assessment.","listText":"Not sure I agree with the Apple assessment.","text":"Not sure I agree with the Apple assessment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9958257664","repostId":"2303708978","repostType":4,"repost":{"id":"2303708978","pubTimestamp":1673755084,"share":"https://www.laohu8.com/m/news/2303708978?lang=&edition=full","pubTime":"2023-01-15 11:58","market":"us","language":"en","title":"3 Warren Buffett Stocks to Avoid Like the Plague in 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2303708978","media":"Motley Fool","summary":"Even the world's greatest investors are wrong from time to time.","content":"<html><head></head><body><p>Pretty much all Warren Buffett has done is win since becoming CEO of <b>Berkshire Hathaway</b> in 1965. Including the 4% gain for Berkshire&#39;s Class A shares (BRK.A) in 2022, the Oracle of Omaha has overseen a greater than 3,700,000% aggregate return for his shareholders since taking the reins.</p><p>However, Buffett isn&#39;t infallible. Even the greatest investors in the world are going to be wrong from time to time. With approximately four dozen securities in Berkshire Hathaway&#39;s investment portfolio, some are bound to underperform.</p><p>As investors continue to steam ahead into the new year, three Warren Buffett stocks stand out as potential underperformers that can be avoided like the plague.</p><h2><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a></h2><p>To be perfectly clear, Buffett and his investment team don&#39;t pile into train wrecks. They tend to buy businesses that offer a long history of profitability and/or present with clear-cut competitive advantages. Cloud data-warehousing company <b>Snowflake</b> falls into the latter camp, with easily identifiable competitive edges.</p><p>Snowflake built its solutions atop the most popular cloud infrastructure services. While it can be difficult to share data across competing cloud infrastructure platforms without Snowflake, data-sharing is seamless for the company&#39;s customers.</p><p>Further, Snowflake has shunned cloud-based subscriptions in favor of a pay-as-you-go model. Customers are charged based on the amount of data stored and Snowflake Compute Credits used. This considerably more transparent payment approach is well liked, as evidenced by Snowflake&#39;s net revenue retention rate of 165% in the October-ended fiscal quarter. This retention rate means existing customers are spending 65% more on a year-over-year basis.</p><p>Despite these advantages, I fully expect Snowflake to underperform the broader market in 2023. With the Federal Reserve rapidly raising interest rates to tame historically high inflation, it&#39;s growth-oriented companies that&#39;ll be hit hardest. If the tea leaves are correct and the U.S. falls into a recession at some point this year, new customer generation and net revenue retention rate would both be expected to slow.</p><p>The other issue that can&#39;t be ignored is its premium valuation. Despite Snowflake stock losing in the neighborhood of 70% since hitting an all-time high of $405 in November 2021, it&#39;s still, arguably, the most expensive cloud stock relative to sales. Even if the company manages the 46% sales growth Wall Street&#39;s consensus is calling for in fiscal 2024 (which covers a good portion of the 2023 calendar year), it&#39;ll still be valued at more than 13 times the $3 billion in revenue analysts expect.</p><p>To add, Snowflake is nowhere close to generating a profit based on generally accepted accounting principles (GAAP). In fact, the company&#39;s GAAP net loss through the first nine months of fiscal 2023 widened to nearly $590 million from $546 million in the comparable period last fiscal year. Value investors aren&#39;t going to want anything to do with Snowflake during a bear market.</p><h2>Kraft Heinz</h2><p>The second Buffett stock to avoid like the plague in 2023 may very well be the worst investment in Berkshire Hathaway&#39;s entire portfolio: <b>Kraft Heinz</b>.</p><p>On one hand, Kraft Heinz is doling out an inflation-fighting 3.8% yield, and it owns a vast portfolio of well-known and beloved prepackaged food brands. This includes Kraft and Heinz, as well as Oscar Mayer, Ore-Ida, Velveeta, and Jell-O, among others.</p><p>Kraft Heinz has also been a clear beneficiary of the COVID-19 pandemic. With consumers choosing to eat at home more often, the company&#39;s prepackaged and easy-to-make meals, snacks, and condiments have received a boost. Through the first nine months of 2022, its organic growth rate clocked in at a blistering 9.5%.</p><p>However, there are a number of red flags to suggest that Kraft Heinz is in for a rough year. For instance, even though organic growth surged 9.5% through the first nine months of 2022, it&#39;s been a function of higher price points and not volume. As a whole, price is up 12.3% and volume is down 2.8%. In my view, this leaves the company exposed to substitution bias from consumers with inflation well above average and the U.S. economy weakening. In other words, consumers could start trading down to store/generic brands that don&#39;t cost as much as the brand-name products Kraft Heinz sells.</p><p>Perhaps the most glaring problem with Kraft Heinz can be found on its balance sheet. Thanks to acquisitions, the company is sitting on $30.6 billion in goodwill -- effectively the premium Kraft Heinz paid above the tangible value of the businesses it&#39;s purchased -- and close to $20.1 billion in long-term debt. What Kraft Heinz really needs is cash to reignite interest in its brands. Unfortunately, the company is constrained by its balance sheet.</p><p>Normally, a consumer staples company with a forward-year price-to-earnings ratio of 15 would be viewed as a safe-haven investment during a bear market. But with virtually no sales growth on the docket for 2023, and the company&#39;s balance sheet still a mess, it stands out as an easy stock to avoid.</p><h2>Apple</h2><p>The third and final Buffett stock to avoid like the plague is none other than Berkshire Hathaway&#39;s largest holding, tech stock <b>Apple</b>.</p><p>To reiterate, once again, Buffett and his team invest in high-quality businesses. But even top-notch companies can have bad years.</p><p>On the plus side, Apple has led with innovation. The company&#39;s iPhone accounts for approximately half of all U.S. smartphone market share. What&#39;s more, Apple&#39;s ongoing shift to subscription services should provide a sustained lift on its operating margin and help to reduce the revenue ebbs and flows associated with physical product replacement cycles.</p><p>Apple also has the most impressive capital-return program on the planet. Since the beginning of 2013, Apple has repurchased an almost unfathomable $554 billion worth of its common stock. Not including itself, that&#39;s more than the market cap of all but four other <b>S&amp;P 500</b> companies.</p><p>On the other side of the coin, Apple&#39;s iPhone 14 failed to provide a lot of differentiation from its preceding model. As a result, Apple ramped down plans to boost iPhone production this past September. Since the iPhone is its top-selling product, this bodes poorly for revenue growth over the next couple of quarters.</p><p>The other issue for Apple is that rapidly rising interest rates have walled off its access to cheap capital. Even though Apple generates plenty of operating cash flow, it had previously turned to the debt market to raise money for share repurchases. With rates rapidly rising, it wouldn&#39;t be a surprise to see Apple&#39;s share repurchases tail off in 2023.</p><p>As I stated earlier this week, Apple trading at a price-to-earnings multiple of 21 for the current year isn&#39;t egregious. But with the company only slated to grow sales by 2% or 3% this year, it simply isn&#39;t a good value. I fully expect Apple stock to fall below $100 this year, which makes it a Buffett stock to avoid.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Warren Buffett Stocks to Avoid Like the Plague in 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Warren Buffett Stocks to Avoid Like the Plague in 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-15 11:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/01/13/3-warren-buffett-stocks-avoid-like-plague-in-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pretty much all Warren Buffett has done is win since becoming CEO of Berkshire Hathaway in 1965. Including the 4% gain for Berkshire's Class A shares (BRK.A) in 2022, the Oracle of Omaha has overseen ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/01/13/3-warren-buffett-stocks-avoid-like-plague-in-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KHC":"卡夫亨氏","SNOW":"Snowflake","AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2023/01/13/3-warren-buffett-stocks-avoid-like-plague-in-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2303708978","content_text":"Pretty much all Warren Buffett has done is win since becoming CEO of Berkshire Hathaway in 1965. Including the 4% gain for Berkshire's Class A shares (BRK.A) in 2022, the Oracle of Omaha has overseen a greater than 3,700,000% aggregate return for his shareholders since taking the reins.However, Buffett isn't infallible. Even the greatest investors in the world are going to be wrong from time to time. With approximately four dozen securities in Berkshire Hathaway's investment portfolio, some are bound to underperform.As investors continue to steam ahead into the new year, three Warren Buffett stocks stand out as potential underperformers that can be avoided like the plague.SnowflakeTo be perfectly clear, Buffett and his investment team don't pile into train wrecks. They tend to buy businesses that offer a long history of profitability and/or present with clear-cut competitive advantages. Cloud data-warehousing company Snowflake falls into the latter camp, with easily identifiable competitive edges.Snowflake built its solutions atop the most popular cloud infrastructure services. While it can be difficult to share data across competing cloud infrastructure platforms without Snowflake, data-sharing is seamless for the company's customers.Further, Snowflake has shunned cloud-based subscriptions in favor of a pay-as-you-go model. Customers are charged based on the amount of data stored and Snowflake Compute Credits used. This considerably more transparent payment approach is well liked, as evidenced by Snowflake's net revenue retention rate of 165% in the October-ended fiscal quarter. This retention rate means existing customers are spending 65% more on a year-over-year basis.Despite these advantages, I fully expect Snowflake to underperform the broader market in 2023. With the Federal Reserve rapidly raising interest rates to tame historically high inflation, it's growth-oriented companies that'll be hit hardest. If the tea leaves are correct and the U.S. falls into a recession at some point this year, new customer generation and net revenue retention rate would both be expected to slow.The other issue that can't be ignored is its premium valuation. Despite Snowflake stock losing in the neighborhood of 70% since hitting an all-time high of $405 in November 2021, it's still, arguably, the most expensive cloud stock relative to sales. Even if the company manages the 46% sales growth Wall Street's consensus is calling for in fiscal 2024 (which covers a good portion of the 2023 calendar year), it'll still be valued at more than 13 times the $3 billion in revenue analysts expect.To add, Snowflake is nowhere close to generating a profit based on generally accepted accounting principles (GAAP). In fact, the company's GAAP net loss through the first nine months of fiscal 2023 widened to nearly $590 million from $546 million in the comparable period last fiscal year. Value investors aren't going to want anything to do with Snowflake during a bear market.Kraft HeinzThe second Buffett stock to avoid like the plague in 2023 may very well be the worst investment in Berkshire Hathaway's entire portfolio: Kraft Heinz.On one hand, Kraft Heinz is doling out an inflation-fighting 3.8% yield, and it owns a vast portfolio of well-known and beloved prepackaged food brands. This includes Kraft and Heinz, as well as Oscar Mayer, Ore-Ida, Velveeta, and Jell-O, among others.Kraft Heinz has also been a clear beneficiary of the COVID-19 pandemic. With consumers choosing to eat at home more often, the company's prepackaged and easy-to-make meals, snacks, and condiments have received a boost. Through the first nine months of 2022, its organic growth rate clocked in at a blistering 9.5%.However, there are a number of red flags to suggest that Kraft Heinz is in for a rough year. For instance, even though organic growth surged 9.5% through the first nine months of 2022, it's been a function of higher price points and not volume. As a whole, price is up 12.3% and volume is down 2.8%. In my view, this leaves the company exposed to substitution bias from consumers with inflation well above average and the U.S. economy weakening. In other words, consumers could start trading down to store/generic brands that don't cost as much as the brand-name products Kraft Heinz sells.Perhaps the most glaring problem with Kraft Heinz can be found on its balance sheet. Thanks to acquisitions, the company is sitting on $30.6 billion in goodwill -- effectively the premium Kraft Heinz paid above the tangible value of the businesses it's purchased -- and close to $20.1 billion in long-term debt. What Kraft Heinz really needs is cash to reignite interest in its brands. Unfortunately, the company is constrained by its balance sheet.Normally, a consumer staples company with a forward-year price-to-earnings ratio of 15 would be viewed as a safe-haven investment during a bear market. But with virtually no sales growth on the docket for 2023, and the company's balance sheet still a mess, it stands out as an easy stock to avoid.AppleThe third and final Buffett stock to avoid like the plague is none other than Berkshire Hathaway's largest holding, tech stock Apple.To reiterate, once again, Buffett and his team invest in high-quality businesses. But even top-notch companies can have bad years.On the plus side, Apple has led with innovation. The company's iPhone accounts for approximately half of all U.S. smartphone market share. What's more, Apple's ongoing shift to subscription services should provide a sustained lift on its operating margin and help to reduce the revenue ebbs and flows associated with physical product replacement cycles.Apple also has the most impressive capital-return program on the planet. Since the beginning of 2013, Apple has repurchased an almost unfathomable $554 billion worth of its common stock. Not including itself, that's more than the market cap of all but four other S&P 500 companies.On the other side of the coin, Apple's iPhone 14 failed to provide a lot of differentiation from its preceding model. As a result, Apple ramped down plans to boost iPhone production this past September. Since the iPhone is its top-selling product, this bodes poorly for revenue growth over the next couple of quarters.The other issue for Apple is that rapidly rising interest rates have walled off its access to cheap capital. Even though Apple generates plenty of operating cash flow, it had previously turned to the debt market to raise money for share repurchases. With rates rapidly rising, it wouldn't be a surprise to see Apple's share repurchases tail off in 2023.As I stated earlier this week, Apple trading at a price-to-earnings multiple of 21 for the current year isn't egregious. But with the company only slated to grow sales by 2% or 3% this year, it simply isn't a good value. I fully expect Apple stock to fall below $100 this year, which makes it a Buffett stock to avoid.","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9054196844,"gmtCreate":1655349560388,"gmtModify":1676535620495,"author":{"id":"4110126448550012","authorId":"4110126448550012","name":"Payneri","avatar":"https://community-static.tradeup.com/news/f523c00ecd00b27a2a30216bac7505e7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GNS\">$Genius Group Limited(GNS)$</a>Looking good!!!","listText":"<a href=\"https://ttm.financial/S/GNS\">$Genius Group Limited(GNS)$</a>Looking good!!!","text":"$Genius Group Limited(GNS)$Looking good!!!","images":[{"img":"https://community-static.tradeup.com/news/9aa99b9c56d9179504e61ffafc476bad","width":"1125","height":"2325"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9054196844","isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9025113756,"gmtCreate":1653636432775,"gmtModify":1676535319026,"author":{"id":"4110126448550012","authorId":"4110126448550012","name":"Payneri","avatar":"https://community-static.tradeup.com/news/f523c00ecd00b27a2a30216bac7505e7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Interesting view","listText":"Interesting view","text":"Interesting view","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9025113756","repostId":"1154795776","repostType":4,"repost":{"id":"1154795776","pubTimestamp":1653628057,"share":"https://www.laohu8.com/m/news/1154795776?lang=&edition=full","pubTime":"2022-05-27 13:07","market":"us","language":"en","title":"7 Undervalued Blue-Chip Stocks to Buy for June","url":"https://stock-news.laohu8.com/highlight/detail?id=1154795776","media":"InvestorPlace","summary":"These undervalued blue-chip stocks possess excellent long-term potential.Micron: Semiconductor stock","content":"<html><head></head><body><p>These undervalued blue-chip stocks possess excellent long-term potential.</p><ul><li><a href=\"https://laohu8.com/S/MU\">Micron</a>: Semiconductor stock that blends growth and low valuation.</li><li><a href=\"https://laohu8.com/S/AA\">Alcoa</a>: Net income growth bodes very well for the commodities giant.</li><li><a href=\"https://laohu8.com/S/NTR\">Nutrien</a>: The undervalued Canadian firm is vital to food production.</li><li><a href=\"https://laohu8.com/S/AIG\">American International Group</a>: AIG’s upside is attractive and its staid dividend smooths current volatility.</li><li><a href=\"https://laohu8.com/S/MMM\">3M</a>: Four straight earnings beats suggest 3M will remain strong, and it’s cheap now.</li><li><a href=\"https://laohu8.com/S/MSFT\">Microsoft</a>: Microsoft continues to perform exceptionally well, but it’s discounted despite its overwhelming buy status.</li><li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>: Vaccine sales will fuel future growth, making Pfizer noteworthy.</li></ul><p>With the ongoing market correction, there are bound to be multiple undervalued blue-chip stocks for sale at excellent prices. For investors who’ve long held positions in these equities, the correction is troublesome. Gains have been erased. Of course, one investor’s loss is often another’s gain — and right now is a strong time to pick up blue-chip stocks while they remain undervalued.</p><p>These stocks are household names and trade with massive market capitalizations. They’re usually industry leaders and often the biggest player in their respective sectors. They boast dependable earnings, substantial operating histories and often pay dividends as well.</p><p>With that said, let’s look at the best deals among undervalued blue-chip stocks to buy in June.</p><p><a href=\"https://laohu8.com/S/MU\">Micron</a><img src=\"https://static.tigerbbs.com/d789740a0d55698fce2eaa27ff334fcb\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Charles Knowles / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/MU\">Micron</a> is a U.S.-based semiconductor company that often fails to garner as much attention as similar firms. That said, there’s plenty to appreciate about it. It makes DRAM, NAND, and NOR memory and storage technology, but is rarely mentioned alongside <b>AMD</b> or <b>Nvidia</b>.</p><p>That said, MU stock is very much worth considering right now. High-level metrics clearly suggest there’s massive upside in it at current prices. The equity boasts an averagetarget stock priceof $111.45 but can be purchased for under $70 currently.</p><p>The reason it’s worth considering is that MU stock is slated to grow as measured by net income while likely increasing its dividend. All the while, it remains cheap based on price-to-earnings (P/E) ratio.</p><p>Its8.5x P/E ratiois well below the 19.16x average across the semiconductor industry. If you want bottom-line growth at a cheap price, Micron is absolutely worth picking up.</p><p><a href=\"https://laohu8.com/S/AA\">Alcoa</a><img src=\"https://static.tigerbbs.com/345c732c89a6bd214adff72fe56d3249\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Daniel J. Macy / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/AA\">Alcoa</a> produces bauxite, alumina and aluminum products. Its business is mundane and by most standards, it isn’t likely to excite investors on that alone. However, the upside in AA stock should.</p><p>It is trading lower over the past few weeks, but it hasn’t lost value overall in 2022. Yes, it possesses upside based on consensus analyst prices. Those estimates suggest a potential increase of nearly 50% at AA stock’s current price.</p><p>The reason investors should believe share prices can rise quickly lies in the bottom-line growth predicted for the firm. In 2021, Alcoa’s $12.2 billion in revenue led to a net income of $429 million.</p><p>In 2022, that revenue isanticipated to increaseby more than 18% to $14.4 billion. That’s nice enough growth, but what really should impress is the notion that Alcoa’s net income is expected to nearly quintuple at the same time. The company’s net income is expected to reach $2.1 billion in 2022.</p><p><a href=\"https://laohu8.com/S/NTR\">Nutrien</a><img src=\"https://static.tigerbbs.com/cf261f41b67b978b2bccc50b86f9619b\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Pavel Kapysh/ShutterStock.com</p><p>It’s hard to read about markets and not come across a headline about the increasing value of food production and cropland. They imply companies like <a href=\"https://laohu8.com/S/NTR\">Nutrien</a>, which produces potash, nitrogen and phosphate, will have more importance moving forward.</p><p>Increasing food production will require more land under cultivation, which in turn requires more fertilizer use that includes the products Nutrien produces. That’s the underlying macroeconomic argument that favors the company.</p><p>The fundamental argument that favors NTR stock is its valuation relative to its peers. The firm’s 13x P/E ratio is slightly lower than the industry median of 15.1x. That is wildly lower than its industry, which is a positive. Stocks that are severely undervalued often suffer due to factors outside of what their fundamentals can explain. In other words, Nutrien is not a value trap.</p><p>The company is growing following recordfirst-quarter earningsof $1.4 billion. Both revenue and profit are expected to continue to surge as the Canadian firm responds to fill the void created by the ongoing war in Ukraine.</p><p><a href=\"https://laohu8.com/S/AIG\">American International Group</a><img src=\"https://static.tigerbbs.com/4fbf6ee441b7aaaccd4fbe0cf78bfd2a\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Evan El-Amin / Shutterstock</p><p>The insurance industry is not an exciting business. Therefore, it is to be expected that insurance stocks carry low valuation metrics. That said,<b>AIG</b>(NYSE:<b><u>AIG</u></b>) stands out among its peers in terms of value.</p><p>The stock’s P/E ratio of 5.8x is roughly half that of the industry overall, which sits at 10.7x. That doesn’t tell us much, because the market could simply prefer an average insurance firm to AIG. If that were the case, then its much lower valuation wouldn’t be an opportunity.</p><p>But it is an opportunity because AIG stock’s median P/E ratio over the last 10 years is 9.85x. That strongly implies once we exit the current market — whenever that may be — then AIG stock should fare much, much better.</p><p>When that capital returns, share prices will rise. Until then, current investors also have a modest and reliable dividend yielding 2.3% to look forward to.</p><p><a href=\"https://laohu8.com/S/MMM\">3M</a><img src=\"https://static.tigerbbs.com/dcfdc62e0b1977b35e871a578f6f8388\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: r.classen / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/MMM\">3M</a> produces a lot of products — in fact,more than 60,000of them. So it’s almost inevitable that you’ve used one or more of them in the past. But it isn’t the breadth of product offerings that makes MMM stock interesting to value investors as much as current prices.</p><p>3M shares began 2022 trading around $180. However, they’ve fallen to a range between $140 and $150 as of early February. They’ve since struggled to escape that range.</p><p>But there’s reason to remain enthusiastic about the firm’s prospects. For one, it has exceeded analyst expectations in each of the past four quarters and provided earnings beats. And each of those four quarters has exceeded the high points of analyst ranges.</p><p>Onevaluationsuggests MMM stock should trade at $186.80 based on several historic multiples.</p><p><a href=\"https://laohu8.com/S/MSFT\">Microsoft</a><img src=\"https://static.tigerbbs.com/998767af9244c24d2eca1a6c74ee6b60\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: The Art of Pics / Shutterstock.com</p><p>When 2022 began, <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> stock was trading at $335. That wasn’t far from its target stock price of $360. So it would have been much harder to proffer the idea that there was massive upside in it back then.</p><p>That was also before inflation was the dominant issue it now is, and the tech wreck hadn’t yet done much damage. Fast forward a few months and the story is vastly different. Microsoft shares trade near $250. However, analysts remain steadfast, with the overwhelming majority rating it a buy.</p><p>Microsoft continues to perform amazingly well, though. Its most recentearningsshowed that revenues increased 18%, reaching $49.4 billion in the quarter. I could go on and on about Microsoft’s impressive results, but the point is that when the market offers MSFT stock cheap, buying just makes sense.</p><p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></p><p><img src=\"https://static.tigerbbs.com/24582c18e5505b72fa27f4466b6dc4db\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: photobyphm / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> received a modest bump on May 20 when it was announced that the Centers for Disease Control and Prevention (CDC) hadcleared its boosterfor use in children ages 5 to 11. While that news indicates a new revenue stream for the company, its prospects moving forward are less about Covid-19 vaccines and more about leveraging the proceeds from that business.</p><p>Investors believe Pfizer is losing its sheen as the pandemic enters its later stages. PFE stock has lost about 5% of its value year-to-date. But it was one of the winners in the race to develop a vaccine for Covid-19. That ensures the company has money to develop and acquire future potential blockbuster drugs.</p><p>It’s now cheap, well-funded and in position to remain so for the long term.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Undervalued Blue-Chip Stocks to Buy for June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Undervalued Blue-Chip Stocks to Buy for June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-27 13:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/7-undervalued-blue-chip-stocks-to-buy-for-june/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These undervalued blue-chip stocks possess excellent long-term potential.Micron: Semiconductor stock that blends growth and low valuation.Alcoa: Net income growth bodes very well for the commodities ...</p>\n\n<a href=\"https://investorplace.com/2022/05/7-undervalued-blue-chip-stocks-to-buy-for-june/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MMM":"3M","NTR":"Nutrien Ltd.","MSFT":"微软","MU":"美光科技","AIG":"美国国际集团","AA":"美国铝业","PFE":"辉瑞"},"source_url":"https://investorplace.com/2022/05/7-undervalued-blue-chip-stocks-to-buy-for-june/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154795776","content_text":"These undervalued blue-chip stocks possess excellent long-term potential.Micron: Semiconductor stock that blends growth and low valuation.Alcoa: Net income growth bodes very well for the commodities giant.Nutrien: The undervalued Canadian firm is vital to food production.American International Group: AIG’s upside is attractive and its staid dividend smooths current volatility.3M: Four straight earnings beats suggest 3M will remain strong, and it’s cheap now.Microsoft: Microsoft continues to perform exceptionally well, but it’s discounted despite its overwhelming buy status.Pfizer: Vaccine sales will fuel future growth, making Pfizer noteworthy.With the ongoing market correction, there are bound to be multiple undervalued blue-chip stocks for sale at excellent prices. For investors who’ve long held positions in these equities, the correction is troublesome. Gains have been erased. Of course, one investor’s loss is often another’s gain — and right now is a strong time to pick up blue-chip stocks while they remain undervalued.These stocks are household names and trade with massive market capitalizations. They’re usually industry leaders and often the biggest player in their respective sectors. They boast dependable earnings, substantial operating histories and often pay dividends as well.With that said, let’s look at the best deals among undervalued blue-chip stocks to buy in June.MicronSource: Charles Knowles / Shutterstock.comMicron is a U.S.-based semiconductor company that often fails to garner as much attention as similar firms. That said, there’s plenty to appreciate about it. It makes DRAM, NAND, and NOR memory and storage technology, but is rarely mentioned alongside AMD or Nvidia.That said, MU stock is very much worth considering right now. High-level metrics clearly suggest there’s massive upside in it at current prices. The equity boasts an averagetarget stock priceof $111.45 but can be purchased for under $70 currently.The reason it’s worth considering is that MU stock is slated to grow as measured by net income while likely increasing its dividend. All the while, it remains cheap based on price-to-earnings (P/E) ratio.Its8.5x P/E ratiois well below the 19.16x average across the semiconductor industry. If you want bottom-line growth at a cheap price, Micron is absolutely worth picking up.AlcoaSource: Daniel J. Macy / Shutterstock.comAlcoa produces bauxite, alumina and aluminum products. Its business is mundane and by most standards, it isn’t likely to excite investors on that alone. However, the upside in AA stock should.It is trading lower over the past few weeks, but it hasn’t lost value overall in 2022. Yes, it possesses upside based on consensus analyst prices. Those estimates suggest a potential increase of nearly 50% at AA stock’s current price.The reason investors should believe share prices can rise quickly lies in the bottom-line growth predicted for the firm. In 2021, Alcoa’s $12.2 billion in revenue led to a net income of $429 million.In 2022, that revenue isanticipated to increaseby more than 18% to $14.4 billion. That’s nice enough growth, but what really should impress is the notion that Alcoa’s net income is expected to nearly quintuple at the same time. The company’s net income is expected to reach $2.1 billion in 2022.NutrienSource: Pavel Kapysh/ShutterStock.comIt’s hard to read about markets and not come across a headline about the increasing value of food production and cropland. They imply companies like Nutrien, which produces potash, nitrogen and phosphate, will have more importance moving forward.Increasing food production will require more land under cultivation, which in turn requires more fertilizer use that includes the products Nutrien produces. That’s the underlying macroeconomic argument that favors the company.The fundamental argument that favors NTR stock is its valuation relative to its peers. The firm’s 13x P/E ratio is slightly lower than the industry median of 15.1x. That is wildly lower than its industry, which is a positive. Stocks that are severely undervalued often suffer due to factors outside of what their fundamentals can explain. In other words, Nutrien is not a value trap.The company is growing following recordfirst-quarter earningsof $1.4 billion. Both revenue and profit are expected to continue to surge as the Canadian firm responds to fill the void created by the ongoing war in Ukraine.American International GroupSource: Evan El-Amin / ShutterstockThe insurance industry is not an exciting business. Therefore, it is to be expected that insurance stocks carry low valuation metrics. That said,AIG(NYSE:AIG) stands out among its peers in terms of value.The stock’s P/E ratio of 5.8x is roughly half that of the industry overall, which sits at 10.7x. That doesn’t tell us much, because the market could simply prefer an average insurance firm to AIG. If that were the case, then its much lower valuation wouldn’t be an opportunity.But it is an opportunity because AIG stock’s median P/E ratio over the last 10 years is 9.85x. That strongly implies once we exit the current market — whenever that may be — then AIG stock should fare much, much better.When that capital returns, share prices will rise. Until then, current investors also have a modest and reliable dividend yielding 2.3% to look forward to.3MSource: r.classen / Shutterstock.com3M produces a lot of products — in fact,more than 60,000of them. So it’s almost inevitable that you’ve used one or more of them in the past. But it isn’t the breadth of product offerings that makes MMM stock interesting to value investors as much as current prices.3M shares began 2022 trading around $180. However, they’ve fallen to a range between $140 and $150 as of early February. They’ve since struggled to escape that range.But there’s reason to remain enthusiastic about the firm’s prospects. For one, it has exceeded analyst expectations in each of the past four quarters and provided earnings beats. And each of those four quarters has exceeded the high points of analyst ranges.Onevaluationsuggests MMM stock should trade at $186.80 based on several historic multiples.MicrosoftSource: The Art of Pics / Shutterstock.comWhen 2022 began, Microsoft stock was trading at $335. That wasn’t far from its target stock price of $360. So it would have been much harder to proffer the idea that there was massive upside in it back then.That was also before inflation was the dominant issue it now is, and the tech wreck hadn’t yet done much damage. Fast forward a few months and the story is vastly different. Microsoft shares trade near $250. However, analysts remain steadfast, with the overwhelming majority rating it a buy.Microsoft continues to perform amazingly well, though. Its most recentearningsshowed that revenues increased 18%, reaching $49.4 billion in the quarter. I could go on and on about Microsoft’s impressive results, but the point is that when the market offers MSFT stock cheap, buying just makes sense.PfizerSource: photobyphm / Shutterstock.comPfizer received a modest bump on May 20 when it was announced that the Centers for Disease Control and Prevention (CDC) hadcleared its boosterfor use in children ages 5 to 11. While that news indicates a new revenue stream for the company, its prospects moving forward are less about Covid-19 vaccines and more about leveraging the proceeds from that business.Investors believe Pfizer is losing its sheen as the pandemic enters its later stages. PFE stock has lost about 5% of its value year-to-date. But it was one of the winners in the race to develop a vaccine for Covid-19. That ensures the company has money to develop and acquire future potential blockbuster drugs.It’s now cheap, well-funded and in position to remain so for the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9958257664,"gmtCreate":1673755775758,"gmtModify":1676538882140,"author":{"id":"4110126448550012","authorId":"4110126448550012","name":"Payneri","avatar":"https://community-static.tradeup.com/news/f523c00ecd00b27a2a30216bac7505e7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Not sure I agree with the Apple assessment.","listText":"Not sure I agree with the Apple assessment.","text":"Not sure I agree with the Apple assessment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9958257664","repostId":"2303708978","repostType":4,"repost":{"id":"2303708978","pubTimestamp":1673755084,"share":"https://www.laohu8.com/m/news/2303708978?lang=&edition=full","pubTime":"2023-01-15 11:58","market":"us","language":"en","title":"3 Warren Buffett Stocks to Avoid Like the Plague in 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2303708978","media":"Motley Fool","summary":"Even the world's greatest investors are wrong from time to time.","content":"<html><head></head><body><p>Pretty much all Warren Buffett has done is win since becoming CEO of <b>Berkshire Hathaway</b> in 1965. Including the 4% gain for Berkshire&#39;s Class A shares (BRK.A) in 2022, the Oracle of Omaha has overseen a greater than 3,700,000% aggregate return for his shareholders since taking the reins.</p><p>However, Buffett isn&#39;t infallible. Even the greatest investors in the world are going to be wrong from time to time. With approximately four dozen securities in Berkshire Hathaway&#39;s investment portfolio, some are bound to underperform.</p><p>As investors continue to steam ahead into the new year, three Warren Buffett stocks stand out as potential underperformers that can be avoided like the plague.</p><h2><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a></h2><p>To be perfectly clear, Buffett and his investment team don&#39;t pile into train wrecks. They tend to buy businesses that offer a long history of profitability and/or present with clear-cut competitive advantages. Cloud data-warehousing company <b>Snowflake</b> falls into the latter camp, with easily identifiable competitive edges.</p><p>Snowflake built its solutions atop the most popular cloud infrastructure services. While it can be difficult to share data across competing cloud infrastructure platforms without Snowflake, data-sharing is seamless for the company&#39;s customers.</p><p>Further, Snowflake has shunned cloud-based subscriptions in favor of a pay-as-you-go model. Customers are charged based on the amount of data stored and Snowflake Compute Credits used. This considerably more transparent payment approach is well liked, as evidenced by Snowflake&#39;s net revenue retention rate of 165% in the October-ended fiscal quarter. This retention rate means existing customers are spending 65% more on a year-over-year basis.</p><p>Despite these advantages, I fully expect Snowflake to underperform the broader market in 2023. With the Federal Reserve rapidly raising interest rates to tame historically high inflation, it&#39;s growth-oriented companies that&#39;ll be hit hardest. If the tea leaves are correct and the U.S. falls into a recession at some point this year, new customer generation and net revenue retention rate would both be expected to slow.</p><p>The other issue that can&#39;t be ignored is its premium valuation. Despite Snowflake stock losing in the neighborhood of 70% since hitting an all-time high of $405 in November 2021, it&#39;s still, arguably, the most expensive cloud stock relative to sales. Even if the company manages the 46% sales growth Wall Street&#39;s consensus is calling for in fiscal 2024 (which covers a good portion of the 2023 calendar year), it&#39;ll still be valued at more than 13 times the $3 billion in revenue analysts expect.</p><p>To add, Snowflake is nowhere close to generating a profit based on generally accepted accounting principles (GAAP). In fact, the company&#39;s GAAP net loss through the first nine months of fiscal 2023 widened to nearly $590 million from $546 million in the comparable period last fiscal year. Value investors aren&#39;t going to want anything to do with Snowflake during a bear market.</p><h2>Kraft Heinz</h2><p>The second Buffett stock to avoid like the plague in 2023 may very well be the worst investment in Berkshire Hathaway&#39;s entire portfolio: <b>Kraft Heinz</b>.</p><p>On one hand, Kraft Heinz is doling out an inflation-fighting 3.8% yield, and it owns a vast portfolio of well-known and beloved prepackaged food brands. This includes Kraft and Heinz, as well as Oscar Mayer, Ore-Ida, Velveeta, and Jell-O, among others.</p><p>Kraft Heinz has also been a clear beneficiary of the COVID-19 pandemic. With consumers choosing to eat at home more often, the company&#39;s prepackaged and easy-to-make meals, snacks, and condiments have received a boost. Through the first nine months of 2022, its organic growth rate clocked in at a blistering 9.5%.</p><p>However, there are a number of red flags to suggest that Kraft Heinz is in for a rough year. For instance, even though organic growth surged 9.5% through the first nine months of 2022, it&#39;s been a function of higher price points and not volume. As a whole, price is up 12.3% and volume is down 2.8%. In my view, this leaves the company exposed to substitution bias from consumers with inflation well above average and the U.S. economy weakening. In other words, consumers could start trading down to store/generic brands that don&#39;t cost as much as the brand-name products Kraft Heinz sells.</p><p>Perhaps the most glaring problem with Kraft Heinz can be found on its balance sheet. Thanks to acquisitions, the company is sitting on $30.6 billion in goodwill -- effectively the premium Kraft Heinz paid above the tangible value of the businesses it&#39;s purchased -- and close to $20.1 billion in long-term debt. What Kraft Heinz really needs is cash to reignite interest in its brands. Unfortunately, the company is constrained by its balance sheet.</p><p>Normally, a consumer staples company with a forward-year price-to-earnings ratio of 15 would be viewed as a safe-haven investment during a bear market. But with virtually no sales growth on the docket for 2023, and the company&#39;s balance sheet still a mess, it stands out as an easy stock to avoid.</p><h2>Apple</h2><p>The third and final Buffett stock to avoid like the plague is none other than Berkshire Hathaway&#39;s largest holding, tech stock <b>Apple</b>.</p><p>To reiterate, once again, Buffett and his team invest in high-quality businesses. But even top-notch companies can have bad years.</p><p>On the plus side, Apple has led with innovation. The company&#39;s iPhone accounts for approximately half of all U.S. smartphone market share. What&#39;s more, Apple&#39;s ongoing shift to subscription services should provide a sustained lift on its operating margin and help to reduce the revenue ebbs and flows associated with physical product replacement cycles.</p><p>Apple also has the most impressive capital-return program on the planet. Since the beginning of 2013, Apple has repurchased an almost unfathomable $554 billion worth of its common stock. Not including itself, that&#39;s more than the market cap of all but four other <b>S&amp;P 500</b> companies.</p><p>On the other side of the coin, Apple&#39;s iPhone 14 failed to provide a lot of differentiation from its preceding model. As a result, Apple ramped down plans to boost iPhone production this past September. Since the iPhone is its top-selling product, this bodes poorly for revenue growth over the next couple of quarters.</p><p>The other issue for Apple is that rapidly rising interest rates have walled off its access to cheap capital. Even though Apple generates plenty of operating cash flow, it had previously turned to the debt market to raise money for share repurchases. With rates rapidly rising, it wouldn&#39;t be a surprise to see Apple&#39;s share repurchases tail off in 2023.</p><p>As I stated earlier this week, Apple trading at a price-to-earnings multiple of 21 for the current year isn&#39;t egregious. But with the company only slated to grow sales by 2% or 3% this year, it simply isn&#39;t a good value. I fully expect Apple stock to fall below $100 this year, which makes it a Buffett stock to avoid.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Warren Buffett Stocks to Avoid Like the Plague in 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Warren Buffett Stocks to Avoid Like the Plague in 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-15 11:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/01/13/3-warren-buffett-stocks-avoid-like-plague-in-2023/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pretty much all Warren Buffett has done is win since becoming CEO of Berkshire Hathaway in 1965. Including the 4% gain for Berkshire's Class A shares (BRK.A) in 2022, the Oracle of Omaha has overseen ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/01/13/3-warren-buffett-stocks-avoid-like-plague-in-2023/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KHC":"卡夫亨氏","SNOW":"Snowflake","AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2023/01/13/3-warren-buffett-stocks-avoid-like-plague-in-2023/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2303708978","content_text":"Pretty much all Warren Buffett has done is win since becoming CEO of Berkshire Hathaway in 1965. Including the 4% gain for Berkshire's Class A shares (BRK.A) in 2022, the Oracle of Omaha has overseen a greater than 3,700,000% aggregate return for his shareholders since taking the reins.However, Buffett isn't infallible. Even the greatest investors in the world are going to be wrong from time to time. With approximately four dozen securities in Berkshire Hathaway's investment portfolio, some are bound to underperform.As investors continue to steam ahead into the new year, three Warren Buffett stocks stand out as potential underperformers that can be avoided like the plague.SnowflakeTo be perfectly clear, Buffett and his investment team don't pile into train wrecks. They tend to buy businesses that offer a long history of profitability and/or present with clear-cut competitive advantages. Cloud data-warehousing company Snowflake falls into the latter camp, with easily identifiable competitive edges.Snowflake built its solutions atop the most popular cloud infrastructure services. While it can be difficult to share data across competing cloud infrastructure platforms without Snowflake, data-sharing is seamless for the company's customers.Further, Snowflake has shunned cloud-based subscriptions in favor of a pay-as-you-go model. Customers are charged based on the amount of data stored and Snowflake Compute Credits used. This considerably more transparent payment approach is well liked, as evidenced by Snowflake's net revenue retention rate of 165% in the October-ended fiscal quarter. This retention rate means existing customers are spending 65% more on a year-over-year basis.Despite these advantages, I fully expect Snowflake to underperform the broader market in 2023. With the Federal Reserve rapidly raising interest rates to tame historically high inflation, it's growth-oriented companies that'll be hit hardest. If the tea leaves are correct and the U.S. falls into a recession at some point this year, new customer generation and net revenue retention rate would both be expected to slow.The other issue that can't be ignored is its premium valuation. Despite Snowflake stock losing in the neighborhood of 70% since hitting an all-time high of $405 in November 2021, it's still, arguably, the most expensive cloud stock relative to sales. Even if the company manages the 46% sales growth Wall Street's consensus is calling for in fiscal 2024 (which covers a good portion of the 2023 calendar year), it'll still be valued at more than 13 times the $3 billion in revenue analysts expect.To add, Snowflake is nowhere close to generating a profit based on generally accepted accounting principles (GAAP). In fact, the company's GAAP net loss through the first nine months of fiscal 2023 widened to nearly $590 million from $546 million in the comparable period last fiscal year. Value investors aren't going to want anything to do with Snowflake during a bear market.Kraft HeinzThe second Buffett stock to avoid like the plague in 2023 may very well be the worst investment in Berkshire Hathaway's entire portfolio: Kraft Heinz.On one hand, Kraft Heinz is doling out an inflation-fighting 3.8% yield, and it owns a vast portfolio of well-known and beloved prepackaged food brands. This includes Kraft and Heinz, as well as Oscar Mayer, Ore-Ida, Velveeta, and Jell-O, among others.Kraft Heinz has also been a clear beneficiary of the COVID-19 pandemic. With consumers choosing to eat at home more often, the company's prepackaged and easy-to-make meals, snacks, and condiments have received a boost. Through the first nine months of 2022, its organic growth rate clocked in at a blistering 9.5%.However, there are a number of red flags to suggest that Kraft Heinz is in for a rough year. For instance, even though organic growth surged 9.5% through the first nine months of 2022, it's been a function of higher price points and not volume. As a whole, price is up 12.3% and volume is down 2.8%. In my view, this leaves the company exposed to substitution bias from consumers with inflation well above average and the U.S. economy weakening. In other words, consumers could start trading down to store/generic brands that don't cost as much as the brand-name products Kraft Heinz sells.Perhaps the most glaring problem with Kraft Heinz can be found on its balance sheet. Thanks to acquisitions, the company is sitting on $30.6 billion in goodwill -- effectively the premium Kraft Heinz paid above the tangible value of the businesses it's purchased -- and close to $20.1 billion in long-term debt. What Kraft Heinz really needs is cash to reignite interest in its brands. Unfortunately, the company is constrained by its balance sheet.Normally, a consumer staples company with a forward-year price-to-earnings ratio of 15 would be viewed as a safe-haven investment during a bear market. But with virtually no sales growth on the docket for 2023, and the company's balance sheet still a mess, it stands out as an easy stock to avoid.AppleThe third and final Buffett stock to avoid like the plague is none other than Berkshire Hathaway's largest holding, tech stock Apple.To reiterate, once again, Buffett and his team invest in high-quality businesses. But even top-notch companies can have bad years.On the plus side, Apple has led with innovation. The company's iPhone accounts for approximately half of all U.S. smartphone market share. What's more, Apple's ongoing shift to subscription services should provide a sustained lift on its operating margin and help to reduce the revenue ebbs and flows associated with physical product replacement cycles.Apple also has the most impressive capital-return program on the planet. Since the beginning of 2013, Apple has repurchased an almost unfathomable $554 billion worth of its common stock. Not including itself, that's more than the market cap of all but four other S&P 500 companies.On the other side of the coin, Apple's iPhone 14 failed to provide a lot of differentiation from its preceding model. As a result, Apple ramped down plans to boost iPhone production this past September. Since the iPhone is its top-selling product, this bodes poorly for revenue growth over the next couple of quarters.The other issue for Apple is that rapidly rising interest rates have walled off its access to cheap capital. Even though Apple generates plenty of operating cash flow, it had previously turned to the debt market to raise money for share repurchases. With rates rapidly rising, it wouldn't be a surprise to see Apple's share repurchases tail off in 2023.As I stated earlier this week, Apple trading at a price-to-earnings multiple of 21 for the current year isn't egregious. But with the company only slated to grow sales by 2% or 3% this year, it simply isn't a good value. I fully expect Apple stock to fall below $100 this year, which makes it a Buffett stock to avoid.","news_type":1},"isVote":1,"tweetType":1,"viewCount":88,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9054196844,"gmtCreate":1655349560388,"gmtModify":1676535620495,"author":{"id":"4110126448550012","authorId":"4110126448550012","name":"Payneri","avatar":"https://community-static.tradeup.com/news/f523c00ecd00b27a2a30216bac7505e7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GNS\">$Genius Group Limited(GNS)$</a>Looking good!!!","listText":"<a href=\"https://ttm.financial/S/GNS\">$Genius Group Limited(GNS)$</a>Looking good!!!","text":"$Genius Group Limited(GNS)$Looking good!!!","images":[{"img":"https://community-static.tradeup.com/news/9aa99b9c56d9179504e61ffafc476bad","width":"1125","height":"2325"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9054196844","isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9025113756,"gmtCreate":1653636432775,"gmtModify":1676535319026,"author":{"id":"4110126448550012","authorId":"4110126448550012","name":"Payneri","avatar":"https://community-static.tradeup.com/news/f523c00ecd00b27a2a30216bac7505e7","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Interesting view","listText":"Interesting view","text":"Interesting view","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9025113756","repostId":"1154795776","repostType":4,"repost":{"id":"1154795776","pubTimestamp":1653628057,"share":"https://www.laohu8.com/m/news/1154795776?lang=&edition=full","pubTime":"2022-05-27 13:07","market":"us","language":"en","title":"7 Undervalued Blue-Chip Stocks to Buy for June","url":"https://stock-news.laohu8.com/highlight/detail?id=1154795776","media":"InvestorPlace","summary":"These undervalued blue-chip stocks possess excellent long-term potential.Micron: Semiconductor stock","content":"<html><head></head><body><p>These undervalued blue-chip stocks possess excellent long-term potential.</p><ul><li><a href=\"https://laohu8.com/S/MU\">Micron</a>: Semiconductor stock that blends growth and low valuation.</li><li><a href=\"https://laohu8.com/S/AA\">Alcoa</a>: Net income growth bodes very well for the commodities giant.</li><li><a href=\"https://laohu8.com/S/NTR\">Nutrien</a>: The undervalued Canadian firm is vital to food production.</li><li><a href=\"https://laohu8.com/S/AIG\">American International Group</a>: AIG’s upside is attractive and its staid dividend smooths current volatility.</li><li><a href=\"https://laohu8.com/S/MMM\">3M</a>: Four straight earnings beats suggest 3M will remain strong, and it’s cheap now.</li><li><a href=\"https://laohu8.com/S/MSFT\">Microsoft</a>: Microsoft continues to perform exceptionally well, but it’s discounted despite its overwhelming buy status.</li><li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>: Vaccine sales will fuel future growth, making Pfizer noteworthy.</li></ul><p>With the ongoing market correction, there are bound to be multiple undervalued blue-chip stocks for sale at excellent prices. For investors who’ve long held positions in these equities, the correction is troublesome. Gains have been erased. Of course, one investor’s loss is often another’s gain — and right now is a strong time to pick up blue-chip stocks while they remain undervalued.</p><p>These stocks are household names and trade with massive market capitalizations. They’re usually industry leaders and often the biggest player in their respective sectors. They boast dependable earnings, substantial operating histories and often pay dividends as well.</p><p>With that said, let’s look at the best deals among undervalued blue-chip stocks to buy in June.</p><p><a href=\"https://laohu8.com/S/MU\">Micron</a><img src=\"https://static.tigerbbs.com/d789740a0d55698fce2eaa27ff334fcb\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Charles Knowles / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/MU\">Micron</a> is a U.S.-based semiconductor company that often fails to garner as much attention as similar firms. That said, there’s plenty to appreciate about it. It makes DRAM, NAND, and NOR memory and storage technology, but is rarely mentioned alongside <b>AMD</b> or <b>Nvidia</b>.</p><p>That said, MU stock is very much worth considering right now. High-level metrics clearly suggest there’s massive upside in it at current prices. The equity boasts an averagetarget stock priceof $111.45 but can be purchased for under $70 currently.</p><p>The reason it’s worth considering is that MU stock is slated to grow as measured by net income while likely increasing its dividend. All the while, it remains cheap based on price-to-earnings (P/E) ratio.</p><p>Its8.5x P/E ratiois well below the 19.16x average across the semiconductor industry. If you want bottom-line growth at a cheap price, Micron is absolutely worth picking up.</p><p><a href=\"https://laohu8.com/S/AA\">Alcoa</a><img src=\"https://static.tigerbbs.com/345c732c89a6bd214adff72fe56d3249\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Daniel J. Macy / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/AA\">Alcoa</a> produces bauxite, alumina and aluminum products. Its business is mundane and by most standards, it isn’t likely to excite investors on that alone. However, the upside in AA stock should.</p><p>It is trading lower over the past few weeks, but it hasn’t lost value overall in 2022. Yes, it possesses upside based on consensus analyst prices. Those estimates suggest a potential increase of nearly 50% at AA stock’s current price.</p><p>The reason investors should believe share prices can rise quickly lies in the bottom-line growth predicted for the firm. In 2021, Alcoa’s $12.2 billion in revenue led to a net income of $429 million.</p><p>In 2022, that revenue isanticipated to increaseby more than 18% to $14.4 billion. That’s nice enough growth, but what really should impress is the notion that Alcoa’s net income is expected to nearly quintuple at the same time. The company’s net income is expected to reach $2.1 billion in 2022.</p><p><a href=\"https://laohu8.com/S/NTR\">Nutrien</a><img src=\"https://static.tigerbbs.com/cf261f41b67b978b2bccc50b86f9619b\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Pavel Kapysh/ShutterStock.com</p><p>It’s hard to read about markets and not come across a headline about the increasing value of food production and cropland. They imply companies like <a href=\"https://laohu8.com/S/NTR\">Nutrien</a>, which produces potash, nitrogen and phosphate, will have more importance moving forward.</p><p>Increasing food production will require more land under cultivation, which in turn requires more fertilizer use that includes the products Nutrien produces. That’s the underlying macroeconomic argument that favors the company.</p><p>The fundamental argument that favors NTR stock is its valuation relative to its peers. The firm’s 13x P/E ratio is slightly lower than the industry median of 15.1x. That is wildly lower than its industry, which is a positive. Stocks that are severely undervalued often suffer due to factors outside of what their fundamentals can explain. In other words, Nutrien is not a value trap.</p><p>The company is growing following recordfirst-quarter earningsof $1.4 billion. Both revenue and profit are expected to continue to surge as the Canadian firm responds to fill the void created by the ongoing war in Ukraine.</p><p><a href=\"https://laohu8.com/S/AIG\">American International Group</a><img src=\"https://static.tigerbbs.com/4fbf6ee441b7aaaccd4fbe0cf78bfd2a\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: Evan El-Amin / Shutterstock</p><p>The insurance industry is not an exciting business. Therefore, it is to be expected that insurance stocks carry low valuation metrics. That said,<b>AIG</b>(NYSE:<b><u>AIG</u></b>) stands out among its peers in terms of value.</p><p>The stock’s P/E ratio of 5.8x is roughly half that of the industry overall, which sits at 10.7x. That doesn’t tell us much, because the market could simply prefer an average insurance firm to AIG. If that were the case, then its much lower valuation wouldn’t be an opportunity.</p><p>But it is an opportunity because AIG stock’s median P/E ratio over the last 10 years is 9.85x. That strongly implies once we exit the current market — whenever that may be — then AIG stock should fare much, much better.</p><p>When that capital returns, share prices will rise. Until then, current investors also have a modest and reliable dividend yielding 2.3% to look forward to.</p><p><a href=\"https://laohu8.com/S/MMM\">3M</a><img src=\"https://static.tigerbbs.com/dcfdc62e0b1977b35e871a578f6f8388\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: r.classen / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/MMM\">3M</a> produces a lot of products — in fact,more than 60,000of them. So it’s almost inevitable that you’ve used one or more of them in the past. But it isn’t the breadth of product offerings that makes MMM stock interesting to value investors as much as current prices.</p><p>3M shares began 2022 trading around $180. However, they’ve fallen to a range between $140 and $150 as of early February. They’ve since struggled to escape that range.</p><p>But there’s reason to remain enthusiastic about the firm’s prospects. For one, it has exceeded analyst expectations in each of the past four quarters and provided earnings beats. And each of those four quarters has exceeded the high points of analyst ranges.</p><p>Onevaluationsuggests MMM stock should trade at $186.80 based on several historic multiples.</p><p><a href=\"https://laohu8.com/S/MSFT\">Microsoft</a><img src=\"https://static.tigerbbs.com/998767af9244c24d2eca1a6c74ee6b60\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: The Art of Pics / Shutterstock.com</p><p>When 2022 began, <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> stock was trading at $335. That wasn’t far from its target stock price of $360. So it would have been much harder to proffer the idea that there was massive upside in it back then.</p><p>That was also before inflation was the dominant issue it now is, and the tech wreck hadn’t yet done much damage. Fast forward a few months and the story is vastly different. Microsoft shares trade near $250. However, analysts remain steadfast, with the overwhelming majority rating it a buy.</p><p>Microsoft continues to perform amazingly well, though. Its most recentearningsshowed that revenues increased 18%, reaching $49.4 billion in the quarter. I could go on and on about Microsoft’s impressive results, but the point is that when the market offers MSFT stock cheap, buying just makes sense.</p><p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></p><p><img src=\"https://static.tigerbbs.com/24582c18e5505b72fa27f4466b6dc4db\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Source: photobyphm / Shutterstock.com</p><p><a href=\"https://laohu8.com/S/PFE\">Pfizer</a> received a modest bump on May 20 when it was announced that the Centers for Disease Control and Prevention (CDC) hadcleared its boosterfor use in children ages 5 to 11. While that news indicates a new revenue stream for the company, its prospects moving forward are less about Covid-19 vaccines and more about leveraging the proceeds from that business.</p><p>Investors believe Pfizer is losing its sheen as the pandemic enters its later stages. PFE stock has lost about 5% of its value year-to-date. But it was one of the winners in the race to develop a vaccine for Covid-19. That ensures the company has money to develop and acquire future potential blockbuster drugs.</p><p>It’s now cheap, well-funded and in position to remain so for the long term.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Undervalued Blue-Chip Stocks to Buy for June</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Undervalued Blue-Chip Stocks to Buy for June\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-27 13:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/7-undervalued-blue-chip-stocks-to-buy-for-june/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These undervalued blue-chip stocks possess excellent long-term potential.Micron: Semiconductor stock that blends growth and low valuation.Alcoa: Net income growth bodes very well for the commodities ...</p>\n\n<a href=\"https://investorplace.com/2022/05/7-undervalued-blue-chip-stocks-to-buy-for-june/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MMM":"3M","NTR":"Nutrien Ltd.","MSFT":"微软","MU":"美光科技","AIG":"美国国际集团","AA":"美国铝业","PFE":"辉瑞"},"source_url":"https://investorplace.com/2022/05/7-undervalued-blue-chip-stocks-to-buy-for-june/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154795776","content_text":"These undervalued blue-chip stocks possess excellent long-term potential.Micron: Semiconductor stock that blends growth and low valuation.Alcoa: Net income growth bodes very well for the commodities giant.Nutrien: The undervalued Canadian firm is vital to food production.American International Group: AIG’s upside is attractive and its staid dividend smooths current volatility.3M: Four straight earnings beats suggest 3M will remain strong, and it’s cheap now.Microsoft: Microsoft continues to perform exceptionally well, but it’s discounted despite its overwhelming buy status.Pfizer: Vaccine sales will fuel future growth, making Pfizer noteworthy.With the ongoing market correction, there are bound to be multiple undervalued blue-chip stocks for sale at excellent prices. For investors who’ve long held positions in these equities, the correction is troublesome. Gains have been erased. Of course, one investor’s loss is often another’s gain — and right now is a strong time to pick up blue-chip stocks while they remain undervalued.These stocks are household names and trade with massive market capitalizations. They’re usually industry leaders and often the biggest player in their respective sectors. They boast dependable earnings, substantial operating histories and often pay dividends as well.With that said, let’s look at the best deals among undervalued blue-chip stocks to buy in June.MicronSource: Charles Knowles / Shutterstock.comMicron is a U.S.-based semiconductor company that often fails to garner as much attention as similar firms. That said, there’s plenty to appreciate about it. It makes DRAM, NAND, and NOR memory and storage technology, but is rarely mentioned alongside AMD or Nvidia.That said, MU stock is very much worth considering right now. High-level metrics clearly suggest there’s massive upside in it at current prices. The equity boasts an averagetarget stock priceof $111.45 but can be purchased for under $70 currently.The reason it’s worth considering is that MU stock is slated to grow as measured by net income while likely increasing its dividend. All the while, it remains cheap based on price-to-earnings (P/E) ratio.Its8.5x P/E ratiois well below the 19.16x average across the semiconductor industry. If you want bottom-line growth at a cheap price, Micron is absolutely worth picking up.AlcoaSource: Daniel J. Macy / Shutterstock.comAlcoa produces bauxite, alumina and aluminum products. Its business is mundane and by most standards, it isn’t likely to excite investors on that alone. However, the upside in AA stock should.It is trading lower over the past few weeks, but it hasn’t lost value overall in 2022. Yes, it possesses upside based on consensus analyst prices. Those estimates suggest a potential increase of nearly 50% at AA stock’s current price.The reason investors should believe share prices can rise quickly lies in the bottom-line growth predicted for the firm. In 2021, Alcoa’s $12.2 billion in revenue led to a net income of $429 million.In 2022, that revenue isanticipated to increaseby more than 18% to $14.4 billion. That’s nice enough growth, but what really should impress is the notion that Alcoa’s net income is expected to nearly quintuple at the same time. The company’s net income is expected to reach $2.1 billion in 2022.NutrienSource: Pavel Kapysh/ShutterStock.comIt’s hard to read about markets and not come across a headline about the increasing value of food production and cropland. They imply companies like Nutrien, which produces potash, nitrogen and phosphate, will have more importance moving forward.Increasing food production will require more land under cultivation, which in turn requires more fertilizer use that includes the products Nutrien produces. That’s the underlying macroeconomic argument that favors the company.The fundamental argument that favors NTR stock is its valuation relative to its peers. The firm’s 13x P/E ratio is slightly lower than the industry median of 15.1x. That is wildly lower than its industry, which is a positive. Stocks that are severely undervalued often suffer due to factors outside of what their fundamentals can explain. In other words, Nutrien is not a value trap.The company is growing following recordfirst-quarter earningsof $1.4 billion. Both revenue and profit are expected to continue to surge as the Canadian firm responds to fill the void created by the ongoing war in Ukraine.American International GroupSource: Evan El-Amin / ShutterstockThe insurance industry is not an exciting business. Therefore, it is to be expected that insurance stocks carry low valuation metrics. That said,AIG(NYSE:AIG) stands out among its peers in terms of value.The stock’s P/E ratio of 5.8x is roughly half that of the industry overall, which sits at 10.7x. That doesn’t tell us much, because the market could simply prefer an average insurance firm to AIG. If that were the case, then its much lower valuation wouldn’t be an opportunity.But it is an opportunity because AIG stock’s median P/E ratio over the last 10 years is 9.85x. That strongly implies once we exit the current market — whenever that may be — then AIG stock should fare much, much better.When that capital returns, share prices will rise. Until then, current investors also have a modest and reliable dividend yielding 2.3% to look forward to.3MSource: r.classen / Shutterstock.com3M produces a lot of products — in fact,more than 60,000of them. So it’s almost inevitable that you’ve used one or more of them in the past. But it isn’t the breadth of product offerings that makes MMM stock interesting to value investors as much as current prices.3M shares began 2022 trading around $180. However, they’ve fallen to a range between $140 and $150 as of early February. They’ve since struggled to escape that range.But there’s reason to remain enthusiastic about the firm’s prospects. For one, it has exceeded analyst expectations in each of the past four quarters and provided earnings beats. And each of those four quarters has exceeded the high points of analyst ranges.Onevaluationsuggests MMM stock should trade at $186.80 based on several historic multiples.MicrosoftSource: The Art of Pics / Shutterstock.comWhen 2022 began, Microsoft stock was trading at $335. That wasn’t far from its target stock price of $360. So it would have been much harder to proffer the idea that there was massive upside in it back then.That was also before inflation was the dominant issue it now is, and the tech wreck hadn’t yet done much damage. Fast forward a few months and the story is vastly different. Microsoft shares trade near $250. However, analysts remain steadfast, with the overwhelming majority rating it a buy.Microsoft continues to perform amazingly well, though. Its most recentearningsshowed that revenues increased 18%, reaching $49.4 billion in the quarter. I could go on and on about Microsoft’s impressive results, but the point is that when the market offers MSFT stock cheap, buying just makes sense.PfizerSource: photobyphm / Shutterstock.comPfizer received a modest bump on May 20 when it was announced that the Centers for Disease Control and Prevention (CDC) hadcleared its boosterfor use in children ages 5 to 11. While that news indicates a new revenue stream for the company, its prospects moving forward are less about Covid-19 vaccines and more about leveraging the proceeds from that business.Investors believe Pfizer is losing its sheen as the pandemic enters its later stages. PFE stock has lost about 5% of its value year-to-date. But it was one of the winners in the race to develop a vaccine for Covid-19. That ensures the company has money to develop and acquire future potential blockbuster drugs.It’s now cheap, well-funded and in position to remain so for the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":41,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}